STORM Therapeutics Empowers Leadership with Dr. Eric Martin as Chief Development Officer

STORM Therapeutics, a clinical-stage company renowned for its pioneering work in cellular reprogramming through RNA modifications, has announced the appointment of Dr. Eric Martin as Chief Development Officer (CDO). With a robust career spanning over two decades in oncology research and drug development, Dr. Martin brings a wealth of experience to the role, having held senior positions at leading biotech firms and advanced numerous oncology drugs to clinical trial phases. Dr. Martin's expertise lies in biomarker-enabled preclinical discovery and clinical development strategies specifically for targeted and immunomodulatory cancer therapies. His portfolio includes development of therapeutics like Plixorafenib and Exarafenib, which have been crucial in targeting BRAF-mutant tumors and RAF pathways, as well as inhibitors like Bezuclastinib for KIT-driven cancers. In his new role, Dr. Martin will focus on advancing STORM Therapeutics' METTL3 inhibitor, STC-15, directing its clinical development particularly in combination therapies for multiple cancers including NSCLC and melanoma. STORM's CEO, Jerry McMahon, highlighted Dr. Martin's appointment as a strategic enhancement in advancing the company's innovative use of clinical genomics and biomarkers for cancer treatment. The leadership anticipates that Dr. Martin’s experience and insights will pivot STC-15 development to exploit new opportunities informed by emerging clinical activities and translational studies.